The Ultimate Guide to Codon Usage Bias & Optimization
Imagine trying to communicate with someone who speaks the same language but uses a different dialect. You both understand the words, but some phrases might [Read More…]
Ajmal Aseem
Graduated from the University of Kerala with B.Sc. Botany and Biotechnology. Attained Post-Graduation in Biotechnology from the Kerala University of Fisheries and Ocean Science (KUFOS) with the third rank. Conducted various seminars and attended major Science conferences. Done 6 months of internship in ICMR – National Institute of Nutrition, Hyderabad. 5 years of tutoring experience.
Pharma Giants Strike Landmark Deal with U.S. Government to Slash Drug Prices and Onshore Manufacturing
Major pharmaceutical leaders Novartis, Amgen, Gilead, GSK, and Sanofi have signed landmark voluntary agreements with the U.S. government to adopt “Most Favored Nation” pricing. The deal introduces the TrumpRx.gov platform for direct-to-patient savings, slashes prices for critical medications like insulin and Hep C cures, and triggers $150 billion in U.S. manufacturing investments.
Johnson & Johnson’s Imaavy Wins European Commission Approval for Generalized Myasthenia Gravis
Johnson & Johnson has secured European Commission approval for Imaavy (nipocalimab), a novel treatment for generalized myasthenia gravis (gMG). This authorization marks the first FcRn blocker approved in Europe for a broad population that includes both adults and adolescents (aged 12+), offering a new option for sustained disease control.
Novartis Receives FDA Approval for Itvisma, Expanding Gene Therapy to Older Children and Adults with SMA
Novartis has secured FDA approval for Itvisma (onasemnogene abeparvovec-brve), marking a historic milestone as the first gene replacement therapy for spinal muscular atrophy (SMA) available to children aged two and older, teens, and adults. This one-time intrathecal injection offers a “game-changing” new treatment option for patients previously ineligible for gene therapy.
Novo Nordisk Seeks FDA Approval for “Super-Charged” Wegovy Dose; Review Expedited Under New Priority Program
Novo Nordisk has officially filed for FDA approval of a higher, 7.2 mg dose of the weight-loss drug Wegovy®. Submitted under the expedited CNPV program, the new dose promises an accelerated review timeline. Phase 3 trial results indicate the 7.2 mg injection could offer significantly greater weight loss potential than the current standard dose.
U.S. FDA Approves PADCEV® and KEYTRUDA® Combo for Patients with Bladder Cancer
The FDA has granted approval for PADCEV® plus KEYTRUDA® as a perioperative treatment for cisplatin-ineligible patients with muscle-invasive bladder cancer (MIBC). Clinical data reveals the combination reduces the risk of recurrence, progression, or death by 60% compared to surgery alone, marking a major shift in the standard of care.
U.S. FDA Grants Full Approval to Amgen’s IMDELLTRA®, Marking a Significant Advance for Extensive Stage Small Cell Lung Cancer
Amgen’s groundbreaking drug IMDELLTRA has secured full FDA approval for extensive stage SCLC based on compelling Phase 3 data. It reduced the risk of death by 40%, offering a major advance for relapsed patients.
Merck Supercharges Global R&D with Launch of Sustainable High-Performance Computer in Munich
Merck has successfully launched a new, energy-efficient high-performance computer in Munich to accelerate research across its three sectors. Developed with Lenovo ThinkSystem servers featuring Neptune liquid cooling and hosted in an Equinix AI-ready data center, the hybrid cloud system enhances drug discovery, product development, and materials science while supporting Merck’s sustainability goals.
SOPHiA GENETICS and Complete Genomics Partner to Integrate AI Oncology Assays with New Sequencing Platform
SOPHiA GENETICS (NASDAQ: SOPH) and Complete Genomics have announced a collaboration to broaden access to precision oncology testing. The partnership will integrate the AI-powered SOPHiA DDM™ platform with Complete Genomics’ new DNBSEQ-T1+ sequencing system. This will provide a streamlined, sample-to-report workflow for the renowned MSK-IMPACT® (solid tumor) and MSK-ACCESS® (liquid biopsy) assays.
Amgen’s Repatha Slashes Risk of First Heart Attack and Stroke by 25% in Landmark Trial
Amgen‘s cholesterol-lowering medication Repatha® (evolocumab) dramatically reduces the risk of a first major adverse cardiovascular event (MACE) in high-risk patients by 25%, according to groundbreaking [Read More…]
